The invention relates to a pharmaceutical composition comprising the active ingredients rosuvastatin of formula I, with the systematic name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2- yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid or its pharmaceutically acceptable salts, esters, hydrates or solvates, and ezetimibe of formula II, with the systematic name (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one or its pharmaceutically acceptable salts, esters, hydrates or solvates, as well as a preparation method of this pharmaceutical composition. The weight ratio of the layers is 1:2 to 2:1.本發明涉及包含化學式I的活性原料瑞舒伐他汀的藥物組成物，系統名稱(3R,5S,6E)-7-[4-(4-氟苯基)-2-(N-甲基甲磺酰胺)-6-(丙-2-基) 嘧啶-5-基]-3，5-二氫基-6-烯酸或其藥學上可接受的鹽、酯、水合物或溶劑化物，及化學式II的依澤替米貝，系統名稱(3R、4S)-1-(4-氟苯基-3-[(3S)-3-(4-氟苯基)-3-羥丙基]-4-(4-羥苯基) 氮雜環丁-2-酮或其藥學上可接受的鹽、酯、水合物或溶劑化物，以及此醫藥組成物的製備方法。其中各層的重量比為1：2至2：1。
